ADJUVANT PUBLICATIONS & ABSTRACTS

Adjuvant data


Evidence / Adjuvant

Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers

Publication: ASCO 2026, Abstract #561 Authors: Steve Isakoff Title: Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers Abstract Background: Homologous recombination deficiency (HRD) is a biomarker for impaired DNA repair proficiency and genomic instability, associated with sensitivity to DNA-damaging agents. Read More

HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study

Publication: SABCS 2025, Presentation ID: PS3-08-17 Authors: Mahtani et al. Title: HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study Introduction: Women ≥ 70 years of age are less likely to receive chemotherapy (CT) due to Read More

70-Gene Signature High Risk Classification Provides Stronger Prognostic Value Than Histologic Grade in HR+HER2– Early Breast Cancer

Publication: SABCS 2025, Presentation ID: PS5-04-19 Authors: Cobain et al. Title: Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancer Introduction: Pivotal trials of immunotherapy and CDK4/6 inhibitors in early-stage hormone-receptor positive (HR+) HER2 negative (HER2–) breast cancer have Read More

Improved 3-Year IDFS With Anthracycline-Based Therapy for Patients With 70-Gene Signature High 2, Luminal B, HR+HER2- Early-Stage Breast Cancer

Publication: SABCS 2025, Presentation ID: PS2-07-03 Authors: O’Shaugnessy et al. Title:  Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancer Introduction: ABC trials found no significant differences in outcomes among patients with clinically high-risk HR+, HER2- breast cancer when Read More

MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data

Publication: JNCI Cancer Spectrum, August 2025 Authors: Brufsky et al. Title: MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data Abstract Background: Gene expression assays help personalize adjuvant chemotherapy decisions for hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer (EBC). The 70-gene risk of distant-recurrence signature, MammaPrint, Read More